FCF $164m — modest; watch for margin expansion · TTM from SEC filings (OCF − CapEx), four quarters to 03/26.
Rev+56.7%TTM YoYA
Revenue +56.7% — hypergrowth, top decile · Latest four quarters of revenue vs the four before them, from SEC filings.
D/E0.01A-
D/E 0.01 — less debt than most Healthcare peers (≈25th pctile)
P/E79.8xD
P/E 79.8 — most expensive decile in Healthcare (≈95th pctile)
PEG2.03est.C
PEG 2.03 — expensive relative to growth rate · PEG derived: P/E ÷ analysts' expected EPS growth for next year, because this name has no vendor-supplied PEG. When earnings are expected to dip this year, the growth used is the yearly average over this year and next, so a recovery isn't counted as growth.
Targets: 1-year is analyst consensus where covered, 5- and 10-year are model estimates; the DCF is a cross-check, not a target. Methodology
Quality-growth score · 67.1
Quality64.0
Growth99.0
Value47.8
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
vs DCF fair value63% aboveest. fair value ~$49
What the price assumes: free cash flow growing about 28% next year, slowing to 4% a year by year ten — vs a starting rate of ~25% our model takes as the middle of three readings — analyst estimates, last year's revenue growth, and the company's own multi-year record.
Quality signals
Gross profitability82% · Agross profit ÷ total assets — not in the score
ROIC12.2% · B+return on invested capital — leads the quality score
Model-generatedFrom reported fundamentals, checked against the figures above · Editorial standards
Why now
Drug Manufacturers - Specialty & Generic · market cap $6.2b. 4% off the 52-week high of $82.94. Revenue growing +57% — in hypergrowth territory. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $98.00 (implying +23% upside).
Moat
ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 79.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $98.00 (8-analyst consensus) — fundamentals + valuation re-rating. 5 yr $143.48 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $212.85 if current growth sustains into durable earnings power.
KNSA vs the Top Picks average
Pillar
KNSA
Book avg
Diff
Quality
64
83
-19
Growth
99
89
+10
Value
48
76
-28
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
Score history · KNSA
Trend
+11.4 over 82 daily scores
From 55.7 (Jun 22) → 67.1 (now)
One point per daily run; read From → To for the actual range.
KNSA at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
30-day change
+0.0%
90-day change
-6.9%
Forward EPS estimate
$1.62
Over the last 90 days, what analysts expect KNSA to earn is materially lower (-6.9%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Position sizing · KNSA
$
%
%
Shares to buy
25
Position size
$1,995
4.0% of portfolio
Stop price
$59.84
25% below $79.78
$ at risk if stopped
$498.63
budget $500.00 · 1% of portfolio
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Kiniksa Pharmaceuticals International, plc (KNSA) is a Drug Manufacturers - Specialty & Generic company that scores 67.1 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and D/E (A-), while P/E (D) rate weaker. On valuation, KNSA sits about 63% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 28% next year, slowing to 4% a year by year ten.
Is KNSA a good stock to buy?
Bull Rankings scores KNSA 67.1 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A) and D/E (A-). A score is a quantitative screen of Kiniksa Pharmaceuticals International, plc's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does KNSA score 67.1 on Bull Rankings?
The score leans on growth at 99.0 out of 100, with value the weakest pillar at 47.8 — the three combine geometrically, so a weak one cannot be papered over by a strong one. KNSA earns its highest marks on Rev (A) and D/E (A-), and is held back by P/E (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so KNSA is measured against Drug Manufacturers - Specialty & Generic peers, not against the market as a whole.
Is KNSA overvalued or undervalued?
Based on $79.78, KNSA sits about 63% above our discounted-cash-flow fair value — the current price implies free cash flow growing about 28% next year, slowing to 4% a year by year ten. It trades at a 79.8x P/E (graded D). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in KNSA?
Trailing P/E 79.8x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.